Ascendis Pharma A (ASND) Current Assets (2012 - 2026)
Ascendis Pharma A (ASND) posted Current Assets of $1.3 billion for Q1 2026, up 1.79% sequentially from $1.3 billion in Q4 2025, and up 35.56% YoY from $969.3 million in Q1 2025.
Ascendis Pharma A (ASND) Current Assets (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Current Assets for 15 years, with the latest figure at $1.3 billion in Q1 2026.
- Quarterly Current Assets rose 35.56% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 35.56% YoY) and the FY2025 annual result came in at $1.3 billion, up 66.06% from the prior year.
- Current Assets advanced to $1.3 billion in Q1 2026 per ASND's latest filing, from $1.3 billion in the prior quarter.
- Over five years, Current Assets peaked at $1.3 billion in Q1 2026 and troughed at $675.6 million in Q2 2024.
- A 5-year average of $983.7 million and a median of $969.3 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets surged 68.66% in 2022, then plunged 37.81% in 2023.
- Over 5 years, Current Assets stood at $942.2 million in 2022, then fell by 19.75% to $756.1 million in 2023, then climbed by 2.82% to $777.4 million in 2024, then soared by 66.06% to $1.3 billion in 2025, then grew by 1.79% to $1.3 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $1.3 billion, $1.3 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 Bn |
| Dec 31, 2025 | 1.29 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 969.30 Mn |
| Dec 31, 2024 | 777.37 Mn |
| Sep 30, 2024 | 1.07 Bn |
| Jun 30, 2024 | 675.55 Mn |
| Mar 31, 2024 | 721.47 Mn |
| Dec 31, 2023 | 756.09 Mn |
| Sep 30, 2023 | 797.86 Mn |
| Jun 30, 2023 | 737.94 Mn |
| Mar 31, 2023 | 869.24 Mn |
| Dec 31, 2022 | 942.17 Mn |
| Sep 30, 2022 | 1.09 Bn |
| Jun 30, 2022 | 1.19 Bn |
| Mar 31, 2022 | 1.26 Bn |
| Dec 31, 2021 | 794.75 Mn |
| Sep 30, 2021 | 1.13 Bn |
| Jun 30, 2021 | 703.60 Mn |